Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318095 · ClinicalTrials.gov registry record · NA
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
A NA study of Resectable Pancreatic Cancers, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02318095 is a NA study of Resectable Pancreatic Cancers that has completed, run by Duke University. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02318095, a NA study of Resectable Pancreatic Cancers, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This research protocol will evaluate the feasibility of administering neoadjuvant gemcitabine and nab-paclitaxel with hypofractionated, image guided, intensity modulated radiotherapy (HIGRT) in resectable and borderline resectable pancreatic cancer
Conditions Studied
Interventions
- RADIATION Radiation therapy
- DRUG Gemcitabine/nab-Paclitaxel
- OTHER Sugical resection
- DRUG Adjuvant chemotheapy
Study Locations (1)
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-02-17 |
| Est. Completion | 2022-11-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318095
The ClinicalTrials.gov registry entry for NCT02318095 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Resectable Pancreatic Cancers appearing as the primary indexed condition, and to 4 interventions - of which Radiation therapy is the first listed.
NCT02318095 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02318095 about?
NCT02318095 is a clinical study titled "Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer". This research protocol will evaluate the feasibility of administering neoadjuvant gemcitabine and nab-paclitaxel with hypofractionated, image guided, intensity modulated radiotherapy (HIGRT) in resectable and borderline resectable pancreatic cancer
What is the current status of trial NCT02318095?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2015-02-17. Estimated completion is 2022-11-14.
What conditions does trial NCT02318095 study?
This clinical trial studies the following conditions: Resectable Pancreatic Cancers.
What interventions are being tested in trial NCT02318095?
The interventions under investigation include: Radiation therapy (RADIATION), Gemcitabine/nab-Paclitaxel (DRUG), Sugical resection (OTHER), Adjuvant chemotheapy (DRUG).
Who is sponsoring clinical trial NCT02318095?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02318095 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.